IL6 and Alzheimer disease: The interleukin (IL)-6 inhibitor, tocilizumab, reduces cognitive deficits in a mouse model of AD,145 and IL-6 inhibitors are being studied in clinical trials for their efficacy in treating severe SARS-CoV-2 disease.143 Long-term follow-up of these patients will enhance understanding of the role of IL-6 and SARS-CoV-2 in any subsequent neurodegeneration.